$90.5 Million is the total value of Corriente Advisors, LLC's 5 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
FXI | Sell | ISHARES TRput | $12,930,000 | -86.9% | 500,000 | -82.8% | 14.29% | -65.7% |
IWM | Sell | ISHARES TRput | $11,544,000 | -84.9% | 70,000 | -84.4% | 12.76% | -60.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CUE BIOPHARMA INC | 8 | Q3 2021 | 26.7% |
MAXAR TECHNOLOGIES INC | 7 | Q2 2021 | 41.3% |
REATA PHARMACEUTICALS INC | 6 | Q2 2021 | 29.6% |
REPLIMUNE GROUP INC | 5 | Q2 2021 | 12.1% |
APTOSE BIOSCIENCES INC | 5 | Q4 2020 | 18.7% |
CARDIFF ONCOLOGY INC | 5 | Q2 2021 | 9.5% |
DIAMEDICA THERAPEUTICS INC | 5 | Q2 2021 | 2.9% |
TFF PHARMACEUTICALS INC | 4 | Q3 2021 | 15.2% |
INVESCO QQQ TR | 3 | Q3 2022 | 94.7% |
LANTERN PHARMA INC | 3 | Q3 2021 | 13.5% |
View Corriente Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Cue Biopharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
TFF Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
CATABASIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
NAUTILUS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
Maxar Technologies Inc. | November 26, 2019 | 2,920,750 | 4.9% |
CATABASIS PHARMACEUTICALS INC | February 23, 2018 | 1,692,899 | 7.3% |
NEUROLOGIX INC/DE | February 14, 2011 | 16,858,224 | 37.7% |
AMERICAN VANTAGE COMPANIESSold out | February 16, 2010 | 0 | 0.0% |
AspenBio Pharma, Inc.Sold out | February 16, 2010 | 0 | 0.0% |
View Corriente Advisors, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-09 |
13F-HR | 2023-05-10 |
13F-HR | 2023-02-15 |
13F-HR | 2022-11-15 |
13F-HR | 2022-08-16 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-15 |
SC 13G/A | 2022-02-14 |
View Corriente Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.